New treatment tested for severe genital eczema
NCT ID NCT07444801
Summary
This study is observing how well an existing eczema medication called tralokinumab works for adults whose moderate-to-severe eczema specifically affects their genital area. About 30 participants will receive the medication as part of their normal care and be monitored for one year. Researchers will track changes in symptoms, skin appearance, and quality of life using special questionnaires and imaging tools.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (MODERATE-TO-SEVERE) INVOLVING THE GENITAL REGION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CCIM, Institut für Entzündungsmedizin UKSH Lübeck
RECRUITINGLübeck, Schleswig-Holstein, 23538, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Department of Dermatology of the University Hospital Augsburg
RECRUITINGAugsburg, München, 86156, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.